Evidence map›Paper›PMID 37129853›Full record

ArticleACS nano2023

Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.

Chandra Kumar Elechalawar, Geeta Rao, Suresh Kumar Gulla, Maulin Mukeshchandra Patel, Alex Frickenstein, Nicolas Means, Ram Vinod Roy, Leonidas Tsiokas, Sima Asfa, Prasanta Panja and 4 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Chandra Kumar ElechalawarDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Geeta RaoDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Suresh Kumar GullaDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Maulin Mukeshchandra PatelDepartment of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Alex FrickensteinStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Nicolas MeansDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Ram Vinod RoyDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Leonidas TsiokasDepartment of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Sima AsfaDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Prasanta PanjaDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Chinthalapally RaoCenter for Cancer Prevention and Drug Development, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Stefan WilhelmStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States.
Resham BhattacharyaDepartment of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Priyabrata MukherjeeDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.ORCID 0000-0002-0557-0833
University of Oklahoma Health Sciences Center · USUniversity of Oklahoma · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
Use of 3D Quantitative Optical Methods to Optimize Mebendazole Treatment of Ovarian CancerP20GM135009 · NIGMS · UNIVERSITY OF OKLAHOMA · PI Javier Antonio Jo · 2022 to 2026
$13.6M
Molecular Mechanism of Antiangiogenic Properties of Gold NanoparticleR01CA136494 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2009 to 2020
$2.9M
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery systemR01CA253391 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2021 to 2025
$1.7M
Reprogramming Tumor Microenvironment by NanoparticleR01CA213278 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2017 to 2021
$1.7M
UBAP2, A New Molecule in Pancreatic Cancer ProgressionR01CA220237 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2018 to 2022
$1.6M
Exploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA136494NCI NIH HHS R01 CA213278NCI NIH HHS R01 CA220237NCI NIH HHS R01 CA253391NCI NIH HHS R01 CA260449NIGMS NIH HHS P20 GM103639NIGMS NIH HHS P20 GM135009
6 · The paper itself

Abstract

The RAS-transformed cells utilize macropinocytosis to acquire amino acids to support their uncontrolled growth. However, targeting RAS to inhibit macropinocytosis remains a challenge. Here, we report that gold nanoparticles (GNP) inhibit macropinocytosis by decreasing KRAS activation. Using surface-modified and unmodified GNP, we showed that unmodified GNP specifically sequestered both wild-type and mutant KRAS and inhibited its activation, irrespective of growth factor stimulation, while surface-passivated GNP had no effect. Alteration of KRAS activation is reflected on downstream signaling cascades, macropinocytosis and tumor cell growth

Indexed as

Metal NanoparticlesPancreatic NeoplasmsCell Line, TumorCell ProliferationGoldHumansMutationPinocytosisProto-Oncogene Proteins p21(ras)GoldKRAS protein, humanProto-Oncogene Proteins p21(ras)gold nanoparticlesKRASmacropinocytosispancreatic ductal adenocarcinomaRAS

Identifiers

PMID37129853
PMCPMC10718652
OpenAlexW4367669384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.